Xyra, LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Feb 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 19, 2027The maintenance fee for Methods for Reducing the Risk of Strokes by Pharmacotherapy to Reduce the Number and Duration of Atrial Fibrillations (US 11,759,640) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
- 1 fee due Jun 12, 2027The maintenance fee for Methods for Reducing the Risk of Strokes by Pharmacotherapy to Reduce the Number and Duration of Atrial Fibrillations (US 11,839,768) comes due Jun 12, 2027. Unpaid by Dec 13, 2027, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for Methods for Reducing the Risk of Strokes by Pharmacotherapy to Reduce the Number and Duration of Atrial Fibrillations (US 11,975,202) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,498,449 | Antiarrhythmic Precursor Compounds, Methods of Synthesis and Methods of Use In force · High confidence | In force | High confidence | |
| US 9,549,912 | Methods for Treating Atrial Fibrillation In force (reinstated) · Medium confidence | In force (reinstated) | Medium confidence | |
| US 11,759,640 | Methods for Reducing the Risk of Strokes by Pharmacotherapy to Reduce the Number and Duration of Atrial Fibrillations In force · High confidence | In force | High confidence | |
| US 11,839,768 | Methods for Reducing the Risk of Strokes by Pharmacotherapy to Reduce the Number and Duration of Atrial Fibrillations In force · Medium confidence | In force | Medium confidence | |
| US 11,975,202 | Methods for Reducing the Risk of Strokes by Pharmacotherapy to Reduce the Number and Duration of Atrial Fibrillations In force · Medium confidence | In force | Medium confidence | |
| US 12,115,373 | Methods for Reducing the Risk of Strokes by Pharmacotherapy to Reduce the Number and Duration of Atrial Fibrillations In force · Medium confidence | In force | Medium confidence | |
| US 12,551,706 | Methods for Reducing the Risk of Heart Failure or Strokes by Pharmacotherapy to Reduce the Number and Duration of Atrial Fibrillations In force · Medium confidence | In force | Medium confidence | |
| US 12,257,228 | Cardioversion Methods Using Budiodarone In force · High confidence | In force | High confidence | |
| US 12,773,398 | Formulations of Crystalline Budiodarone Form-1 In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 no status recorded